Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Links between NAFLD/NASH and Cardiometabolic Syndrome
Author(s): Sheila Gato , Vanessa García-Fernández , Antonio Gil-Gómez , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Clinical Management of Non-alcoholic Steatohepatitis
Author(s): Carlos Millán-Rodríguez , Carlos Palacios Castelló , María de Regla Caballero-Valderrama , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Liver Stiffness to Assess Central Venous Pressure in HF
Author(s): Nicolas Girerd Added: 1 month ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive… View more

Cardiovascular Renal Metabolic

Heart Failure
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
The 7th Global NAFLD/MASLD Congress
Start date: Jun 24, 2024 End date: Jun 25, 2024
The conference is in production. If you would like to speak at this meeting contactlauren@globalengage.co.uk. NAFLD/MASLD continues to be a huge unmet clinical need globally, and although no therapy has received regulatory approval, there continues to be research advancing ourunderstanding of the disease’s mechanisms. Developments innon-invasivediagnostic biomarkerscontinue to offer the hope… View more

Cardiovascular Renal Metabolic
Author(s): Chim C Lang Added: 3 days ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more

Cardiovascular Renal Metabolic
Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease
Author(s): Federica Piani , Lorenzo Annesi , Claudio Borghi Added: 1 week ago

Heart Failure

Prevention & Chronic Conditions
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
Author(s): William Herrington Added: 1 week ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,… View more

Cardiovascular Renal Metabolic